Boehringer In­gel­heim buys out next-gen ADC play­er NBE-Ther­a­peu­tics in a deal worth up to $1.4B+

Just one day af­ter snag­ging a CD­MO to boost pro­duc­tion of its on­colyt­ic virus and can­cer vac­cine pro­grams, Boehringer In­gel­heim is mak­ing an­oth­er ac­qui­si­tion in the can­cer field.

The Ger­man phar­ma an­nounced Thurs­day it’s buy­ing NBE-Ther­a­peu­tics, a pri­vate biotech based in Basel, Switzer­land, in a deal worth rough­ly $1.43 bil­lion (€1.18 bil­lion) con­tin­gent on reg­u­la­to­ry and clin­i­cal mile­stones. Though not typ­i­cal­ly known as a wheel­er and deal­er, Boehringer tacks on an an­ti­body-drug con­ju­gate plat­form whose lead pro­gram re­cent­ly en­tered Phase I/II stud­ies in triple neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER